Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib neoadjuvant therapy for locally advanced poorly differentiated and anaplastic thyroid cancer
ChiCTR2200057655Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid cancer (ATC), sponsored by West China Hospital of Sichuan University. Primary endpoint: R0/R1 resection rate. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
poorly differentiated thyroid carcinoma (PDTC)anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on ChiCTR2200057655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057655.